Table 2.

Rate constants and other parameters

Parametera	Triple therapy patientsb				Ritonavir monotherapy patientsc
	20485	20497	20490	20496	20491	20446	20449	20452
μC × 100 (d−1)	0.35	0.71	0.38	0.38	2.4	0.97	3.5	0.36
c (d−1)	34	8.5	3.9	7.6	89	4.6	400	10
δ (d−1)
This studyd	2.7	1.3	1.4	1.2	—g	1.2	—	0.55
Notermans et al.e	0.36	0.60	0.89	0.37	0.46	0.52	0.34	0.51
Cavert et al.f	0.11	1.1	1.5	1.2	2.6	0.73	0.37	0.24
KxRT	0.95	0.79	0.71	0.96	0.92	0.89	1.1	1.0
p × 100 (d−1)	1.0	0.75	3.4	1.1	ND	ND	ND	ND
Tc × 10−11	2.9	2.8	1.4	2.0	ND	ND	ND	ND
N	49	210	30	120	—	87	—	360
RT × 10−12	1.8	1.3	1.5	0.49	2.9	0.29	4.6	0.23
k × 1012 (d−1)	6.8	0.52	2.2	0.60	—	0.50	—	0.43
kC× 1016 (d−1)	2.9	0.89	0.10	0.13	5.7	3.1	1900	0.97

ND, not determined. 

^a For all patients, n = 20, α = 1.5 × 10⁻¹⁰ d⁻¹, k_−x = k_r = 8600 d⁻¹, μ = 0.0038 d⁻¹, and π = 0. 

^b For these patients (e_p = e_r = 1 for t ≥ 0), the values of p and T_c are determined simultaneously, with λ = 0 and δ given by the steady-state forms of Eqs. 1–3, from cellular data (5, 12). The values of c and K_xR_Tthen are determined simultaneously, with δ fixed, from viral data (5, 14). 

^c For these patients (e_p = 1 and e_r = 0 for t ≥ 0), the values of c, δ, and K_xR_T are determined simultaneously, with T(t) = T₀, from viral data (5, 14). 

^d Confidence limits on δ, given in Tables 3 and 4, which are published as supplemental material, are broad in some cases; however, the lower limit is typically higher than the estimate of Notermans et al. (14). Estimates of c and K_xR_T are insensitive to the value of δ (unpublished results). 

^e Estimates of δ with second-phase decay caused by long-lived infected cells (14). 

^f Estimates of δ based on counts of infected mononuclear cells at d 0 and 2 of therapy (5). 

^g Indeterminate. We find that any large value of δ is consistent with the data. Estimates of c, K_xR_T, and R_T and calculations for these patients are based on δ → ∞.